• All News
• 2020
• 2019
• 2017
• 2016
• 2015
• 2014

Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast

Nov 23, 2016

Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors

Nov 22, 2016

Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update

Nov 15, 2016

Xenetic Biosciences Announces the Closing of its $10M Public Offering

Nov 7, 2016

Xenetic Biosciences Announces Nasdaq Listing of its Common Stock and Pricing of $10M Public Offering

Nov 1, 2016

Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia

Oct 10, 2016

Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

Sep 22, 2016

Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer

Aug 19, 2016

Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine

Aug 18, 2016

Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors

Jul 11, 2016

• « Previous
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• Next »